Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar 28;1(3):281-8.
doi: 10.18632/aging.100034.

Validation of anti-aging drugs by treating age-related diseases

Mikhail V Blagosklonny  1
Affiliations
Review

Validation of anti-aging drugs by treating age-related diseases

Mikhail V Blagosklonny. Aging (Albany NY). .

Abstract

Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.

Keywords: anti-aging drugs; atherosclerosis; cancer; diseases; metformin; rapamycin; resveratrol.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. The TOR intracellular signaling pathway.
Nutrients, GF (growth factors) and insulin activate the TOR pathway, which is involved in aging and age-related diseases. Other genetic factors and environmental factors (e.g., smoking) contribute to specific age-related diseases. Three potential anti-aging modalities (metformin, calorie restriction and rapamycin) all inhibit the TOR pathway.
Figure 2.
Figure 2.. Re-interpretation of the hyperlipidemic side effect of rapamycin.
Rapamycin activates adipose tissue lipase, thus mobilizing lipids from the fat tissue (lipolysis). This effect imitates starvation. Also, rapamycin inhibits lipoprotein lipase thus preventing utilization of lipids by the fat tissue and blocking lipid uptake by the arterial wall. This results in increase in blood lipids.
See this image and copyright information in PMC

References

    1. Hadley EC, lakatta EG, Morrison-Bogorad M, Warner HR, Hodes RJ. The future of aging therapies. Cell. 2005;120:557–567. - PubMed
    1. Sinclair DA, Guarente L. Unlocking the secrets of longevity genes. Sci Am. 2006;294:48–51. - PubMed
    1. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450:712–716. - PMC - PubMed
    1. Perls T, Kunkel L, Puca A. The genetics of aging. Curr Opin Genet Dev. 2002;12:362–369. - PubMed
    1. Curtis R, Geesaman BJ, DiStefano PS. Ageing and metabolism: drug discovery opportunities. Nat Rev Drug Discov. 2005;4:569–580. - PubMed

LinkOut - more resources